69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR)
Immunocore Holdings Plc has filed to sell 69,271 ADRs through a same-day cashless exercise and sale scheduled for May 26, 2026, with cash settlement brokered by J.P. Morgan Securities LLC. The filing also details recent sales by David Berman, including 11,832 ADRs sold on March 11, 2026, 25,000 on April 8, 2026, and 65,000 on May 21, 2026. The transaction is reported as having a neutral filing impact and sentiment, outlining key figures and definitions related to the Form 144 filing process.
MAY 19·Simply Wall Street▲
How Investors May Respond To Immunocore (IMCR) Q1 Profitability and ESOP-Linked Share Registration
Immunocore Holdings plc (IMCR) reported a profitable Q1 2026 with revenues of US$106.68 million and net income of US$12.97 million, alongside a US$76.48 million shelf registration for shares linked to its employee share ownership plan. This marked a shift to profitability after a loss in 2025 and indicates the company's focus on balancing growth, employee incentives, and capital access. The article suggests investors will now focus on the sustainability of this profitability and the ongoing clinical and commercial progress of KIMMTRAK, the company's main revenue driver, amidst rising R&D spending.
NOV 7·GlobeNewswire→
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity ...
